CEO

Lucy has worked in the biotechnology industry specialising in the discovery of novel therapies for rare epithelial diseases for the last 5 years. Previously the Head of Biology for Neem Biotech she has a PhD in Integrative Neuroscience and is an experienced molecular and cell biologist. Lucy previously worked for as a Fast Stream Researcher for the Welsh Government providing scientific evidence to drive policy.

CFO

Chris has a 15+ year track record, registered with ICAEW and ACCA as both a chartered and certified accountant. He has previously held senior financial positions within international businesses and advised owner-managed and entrepreneurial clients whilst at PwC and other firms. He currently manages his own portfolio of business interests.

Executive Chairman

Thomas has 25 years of experience in building businesses, incubating technologies and creating completely new categories of market from scratch in the field of biotechnology, nutraceuticals, medical devices and animal health/technology. 

Executive Director

Bill Pigg has over 30 years experience in the MedTech industry with companies such as Johnson and Johnson and Smith and Nephew spanning the New Product Development process from early stage research to late stage development and commercialisation. As part of the leadership team at Johnson and Johnson Advanced Wound Care he was part of the team who successfully spun the company out under private equity forming Systagenix and subsequently sold the business back into corporate ownership under Acelity.

For the last 5 years Bill has operated as a consultant working with academia, SMEs and large MedTechs helping them to enhance their product development practices and capabilities. Bill also sits on the board of three Biotech and MedTech companies.

Non-executive Director

Carin has over 30 years of experience as a banker and builder of businesses in nutraceuticals, medical devices and animal health, focusing on solutions to significant problems. She is an investor, experienced board member and Chairs the board of a large international aid organisation.

Scientific Advisor

PI at Dundee University and Co-founder and CSO at TenBio. Expert in rare genetic skin disorders and has developed novel state of the art ex vivo human skin models required for evaluation of drug delivery and efficacy.

Technical Advisor

Previous Managing Director of Fidelta in the Galapagos Group and previously VP Research Operations. Over 30 years’ experience in drug discovery and development with a hugely successful delivery track record.

Non-Executive Director

Damian Marron is an experienced Board Chair and Non-Executive Director, corporate advisor and former serial CEO with a successful track record of value creation through public and venture capital financing, portfolio planning, M&A, licensing agreements and R&D collaborations, both as an executive and in advisory roles. He has notably specialized in immuno-oncology, cell therapy and orphan diseases. Damian is currently Non-Executive Chair of the Board at Targovax ASA, Cytoseek Ltd and Imophoron Ltd and Non-Executive Director at Cantargia AB, Bone Therapeutics SA and Resolys Bio Inc. He is also Head of Biopharma with Treehill Partners, a global pure-play healthcare advisory firm and is a Biotech Advisor to Mendel Partners. Damian has formerly been Chair of the Board of Directors of PepGen Ltd and the CEO at Agalimmune Ltd, TxCell SA, Cytheris SA, and Trophos SA. He is a pharmacologist and cell biologist by training and spent ten years in big pharma R&D.

Clinical Advisor

Consultant Dermatologist and academic lead for dermatology at the University of Birmingham/West Midlands Deanery. He established and heads the half-national Epidermolysis Bullosa service at University Hospitals Birmingham NHS Foundation Trust and is a member of DEBRA international Medical and Scientific Advisory Panel.